Scarica l'app Stockscreener
6.03
14.64%
0.77
Precedente Chiudi:
$5.26
Aprire:
$5.27
Volume 24 ore:
16.49M
Relative Volume:
3.68
Capitalizzazione di mercato:
$590.86M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+7.49%
1M Prestazione:
+15.30%
6M Prestazione:
+69.86%
1 anno Prestazione:
+222.46%
Intervallo 1D:
$5.22
$6.50
Intervallo di 1 settimana:
$5.08
$6.50
Portata 52W:
$1.67
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
6.03 | 513.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
1 Small-Cap Biotech Stock Poised for a Breakout - MSN
American Century Companies Inc. Sells 65,409 Shares of aTyr Pharma, Inc. $ATYR - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on aTyr Pharma stock - Investing.com
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Octagon Capital Advisors LP Acquires 2,652,000 Shares of aTyr Pharma, Inc. $ATYR - MarketBeat
Lead Therapy Trial Fuels aTyr Pharma’s (ATYR) Promising Upside, Leerink Stays Bullish - uk.finance.yahoo.com
Can aTyr Pharma Inc. weather a recessionDip Buying & Safe Entry Point Identification - Lancaster City Council
aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks
Is Summit Therapeutics a Buy, Sell, or Hold Now? - AOL.com
Investors Purchase Large Volume of aTyr Pharma Put Options (NASDAQ:ATYR) - MarketBeat
Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results - MSN
aTyr Pharma (NASDAQ:ATYR) Trading Up 8.1%Should You Buy? - MarketBeat
Multi asset correlation models including aTyr Pharma Inc.Weekly Risk Summary & Growth Focused Stock Reports - Newser
When is the best time to exit aTyr Pharma Inc.July 2025 News Drivers & Consistent Growth Stock Picks - Newser
168,742 Shares in aTyr Pharma, Inc. $ATYR Acquired by Wellington Management Group LLP - MarketBeat
How a Surge in Bearish Options Activity at aTyr Pharma (ATYR) Has Changed Its Investment Story - simplywall.st
Does aTyr Pharma Inc. qualify in momentum factor screeningMarket Movement Recap & Step-by-Step Trade Execution Guides - Newser
aTyr Pharma Inc. stock daily chart insightsEarnings Risk Summary & High Accuracy Trade Signal Alerts - Newser
Price momentum metrics for aTyr Pharma Inc. explainedEarnings Performance Report & AI Powered Market Entry Strategies - Newser
Is aTyr Pharma Inc. a play on infrastructure spendingJuly 2025 Outlook & Fast Moving Stock Trade Plans - خودرو بانک
Employee Equity Incentives and Biotech Valuation: How aTyr Pharma’s Inducement Grants Align with Pipeline Progress - AInvest
Is aTyr Pharma Inc. forming bullish engulfing patternsMarket Sentiment Review & Precise Trade Entry Recommendations - خودرو بانک
What is aTyr Pharma Inc.’s book value per shareQuarterly Trade Report & Fast Momentum Stock Entry Tips - خودرو بانک
We're Hopeful That ATyr Pharma (NASDAQ:ATYR) Will Use Its Cash Wisely - 富途牛牛
Using AI based signals to follow aTyr Pharma Inc.Global Markets & High Accuracy Swing Entry Alerts - Newser
Published on: 2025-09-06 02:07:40 - خودرو بانک
ATyr Pharma's Strategic Talent Retention and Pipeline Momentum Signal Long-Term Value Creation - AInvest
ATyr Pharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATYR Stock News - GuruFocus
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech aTyr Pharma Awards 62,400 Shares to New Employees for Novel tRNA Drug Development Program - Stock Titan
Is aTyr Pharma Inc.’s ROE strong enough2025 Market WrapUp & Safe Entry Trade Reports - خودرو بانک
Can aTyr Pharma Inc. rally from current levels2025 Key Highlights & Weekly High Return Opportunities - Newser
Tick level data insight on aTyr Pharma Inc. volatility2025 Trade Ideas & Real-Time Chart Breakout Alerts - Newser
Block Trades: Is aTyr Pharma Inc. exposed to political riskJuly 2025 Snapshot & Weekly Stock Performance Updates - خودرو بانک
What data driven models say about aTyr Pharma Inc.’s futureProfit Target & Fast Moving Trade Plans - Newser
Visualizing aTyr Pharma Inc. stock with heatmaps2025 Top Decliners & Safe Capital Growth Tips - Newser
Using fundamentals and technicals on aTyr Pharma Inc.Portfolio Value Report & Weekly Momentum Picks - Newser
aTyr Pharma Inc.’s volatility index tracking explainedWeekly Trend Summary & Real-Time Stock Movement Alerts - Newser
Will breakout in aTyr Pharma Inc. lead to full recoveryJuly 2025 Setups & Safe Capital Growth Stock Tips - Newser
aTyr Pharma’s Sharp Intraday Drop: What’s Behind the Move? - AInvest
Volatility clustering patterns for aTyr Pharma Inc.July 2025 PreEarnings & AI Enhanced Trade Execution Alerts - Newser
Heatmap analysis for aTyr Pharma Inc. and competitors2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
Aug Rallies: Is aTyr Pharma Inc.’s ROE strong enoughInsider Buying & Community Verified Trade Signals - خودرو بانک
Is aTyr Pharma Inc. exposed to political riskMarket Risk Report & Daily Growth Stock Investment Tips - خودرو بانک
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):